"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at lanreotide autogel for neuroendocrine tumours of the digestive system that have spread
This trial looked at a drug called lanreotide autogel to stop or slow the growth of neuroendocrine tumours (NETs). It was for people with NETs that couldn’t be removed with an operation or had spread to another part of the body from where it started.
Neuroendocrine tumours are a rare group of cancers that make and release hormones. They normally start in the
Lanreotide autogel is a man made form of a hormone called
This trial compared lanreotide autogel to a dummy drug (
- How well lanreotide autogel slows or shrinks these tumours
- More about the side effects
- More about
quality of life
Summary of results
The trial team found that lanreotide autogel was a useful treatment for people with neuroendocrine tumours that have spread and can’t be removed with an operation.
204 people took part and
- Half had lanreotide autogel injections
- Half had dummy injections (placebo)
On average, people took the drug for 2 years. The researchers looked at whose cancer got worse while having treatment. They found this happened in
- 30 people having lanreotide autogel
- 58 people having the dummy drug
After treatment had finished, the trial team looked at the number of people living without their cancer getting worse. They found this was
- 53 people who had lanreotide
- 26 people who had the dummy drug
Both of the above results were
The researchers also looked at how people rated their quality of life and found there was no difference between the 2 groups.
The side effects of lanreotide autogel were mild and included diarrhoea. A small number of patients had high sugar levels and gallstones but these didn’t cause them any problems.
The trial team concluded that lanreotide autogel worked well for people with neuroendocrine tumours that couldn’t be removed with an operation or had spread and it significantly slowed the growth of the tumours.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Martyn Caplin
Experimental Cancer Medicine Centre (ECMC)